Meet the team that lives life science to support your growth and success.

Deepak Behera is a highly accomplished physician-scientist and strategist with over two decades of leadership experience in the medical, academic, and pharmaceutical sectors. His proficiency in medical affairs, clinical development, and radiopharmaceuticals, has been pivotal to the successful launch and commercialization of two industry-leading products.

His early clinical experience grounded him in practical insights before transitioning to academic translational research at Stanford University. His work at Stanford led to birth of two startups, five early-phase trials, and the co-authorship of two patents, highlighting his innovative approach to nuclear medicine.

Deepak’s transition to the pharmaceutical industry was marked by his impactful roles as Senior Medical Director, Head of Medical Affairs, Strategic Medical Director, and Chief Medical Officer. These positions saw him navigate complex clinical development landscapes, Phase I-III study designs, FDA interactions, and oversee the successful launch of two commercial products. Having worked collaboratively with American, European and Asian companies, Deepak is culturally sensitive and adaptable in a global medical landscape.

As a scholar, Deepak has enriched the medical discourse with over 20 peer-reviewed articles and 15 impactful lectures and presentations. His dedication to the medical community extends beyond his professional roles, as demonstrated by his active involvement in organizations like Adaptive Research, EPPIC Global, IASNM, and MISI. As an industry pioneer, Deepak’s embodies the seamless blend of medical expertise, innovative research, commercial understanding and strategic leadership in medical affairs and radiopharmaceuticals.

Dr. Krause is a highly experienced pharmaceutical executive, board-certified in internal medicine with additional qualifications in geriatrics. With over 30 years of experience in pharmaceutical research, development, and medical affairs, he has successfully led clinical development and medical affairs teams across large and mid-sized public companies, as well as small private start-ups.

Dr. Krause has successfully filed multiple BLAs and NDAs. He led clinical development across several global therapeutic areas at SmithKline Beecham and GlaxoSmithKline. He then served as Chief Medical Officer at Vicuron Pharmaceuticals, which was later acquired by Pfizer, Inc. Most recently, he was the Chief Medical Officer at Genomind, Inc., a private, venture-funded pharmacogenetic testing and medication management company. In addition to clinical development and medical affairs, Dr. Krause has expertise in business development.

Dr. Krause is a Fellow of the American College of Physicians, and author of dozens of scientific publications and numerous abstracts. He has served as a consultant to the Department of Defense, and is a member of Genomind’s Scientific Advisory Board. Dr. Krause is a graduate of the Pennsylvania State University, where he received BAs in Art History and Psychology. He was also named a Centennial Fellow by the College of Liberal Arts. He received his MD degree from Temple University, where he completed his residency in internal medicine.

Jon is an entrepreneurial-minded scientist with over 20 years of research and development experience in the pharma and biotech industry (spanning GSK, Eli Lilly and SynOA Therapeutics). While at GSK he was focused on osteoarthritis therapeutic development through leading and shaping corporate strategy and employing both biologics and small molecule-based approaches to discover and progress clinical candidates. At GSK, Jon’s lab discovered and progressed two molecules to the candidate selection milestone. Thereafter, he led the clinical development effort as Early Development Leader providing experience in drafting protocols and informed consents, investigator brochures as well as regulatory IND submissions and application of Good Clinical Practice guidelines. Jon received his PhD in Pathology and Cell Biology from Thomas Jefferson University where he studied hepatitis B virus immunopathology and the effects of antiviral drug treatment and alcohol consumption on viral replication and gene expression in a novel HBV SCID mouse model he developed.

An accomplished pharmaceutical and biotechnology leader, Dr. Lumsden brings a mix of large and small company experience across U.S. and international markets. Recognized as a networker and team-builder, he has successfully built companies from scratch through IPOs, gaining a deep understanding of capital markets and delivering shareholder value.
Always focused on saving and/or improving patient lives, Dr. Lumsden has worked in many therapeutic areas, including infectious diseases, osteoporosis, women’s health, cardio- renal disease, oncology and inflammation/immunology.

Initially a practicing large animal veterinarian, he was recruited by Merck & Co., Inc. to assist in the U.K launch of IVOMEC (ivermectin). Dr. Lumsden relocated to the U.S. to lead the launch of GASTROGARD (omeprazole) for equines, the first new product launch at the newly formed Merial. Transitioning to human health, global responsibilities at Merck included CRIXIVAN (indinavir), FOSAMAX (alendronate) and NUVARING (etonogestrel/ethinyl estradiol). Leading cross-functional teams gave Dr. Lumsden experience across commercialization, clinical and non-clinical development, regulatory, CMC, finance, intellectual property, patent litigation and governmental affairs. He played a key role on the integration team during the acquisition by Merck of Schering Plough (SP), concluding in global responsibility for one of the legacy SP businesses.

His experience in the biotechnology world started with an opportunity to lead Motif Bio from a medicinal chemistry base, building a team from scratch, through the acquisition of a clinical stage antibacterial, iclaprim, completing two IPOs, raising over $125 million from the public markets, the successful completion of two Phase 3 clinical studies and submission of an NDA to FDA. Broad and deep experience of M&A was gained seeking commercialization partners and in-license candidates. Additional CEO and Board experience at private biotechnology companies has encompassed fund-raising, corporate restructuring, financial audits, cap table cleansing, and recruitment/management of CROs (clinical and non-clinical).

Dr. Lumsden is currently a member of the Board of Directors at Kibow Therapeutics, Inc., a profitable consumer and veterinary microbiome therapeutics business with a live biotherapeutic product in Phase 2 clinical development for patients with Stage 4 CKD.

With over forty years of experience in oncology and nuclear medicine, Dr. McEwan is a world-renowned expert in his field. Most recently, he was Chief Medical Officer at Ariceum, a company developing novel medicines for systemic targeted radiotherapy (SRT), and immediately prior to that he was Vice President of Radiopharmaceuticals at Ipsen. As an academic physician, Dr. McEwan served as Chair of the Departments of Radiology and Oncology at the University of Alberta. Dr. McEwan has worked as a physician at Alberta Health Services for over thirty years, with additional postings that have included Clinical Director of the Cross Cancer Institute and Clinical Head of Diagnostic Imaging at the University of Alberta Hospital. Dr. McEwan has authored over 120 publications in oncology and radiopharmaceuticals and SRT.

Elliot is passionate about growing businesses through aggressive digital marketing tactics, and currently pursues this passion as Partner and Chief Marketer at Bracken Marketing. His previous roles have included small startups, major b2b tech players, and project managing across VC portfolios.

When asked about how and why his career brought him to joining the Bracken founding team he states: “The high-tech industry I once worked in became overcrowded. But now is the perfect time to apply the marketing strategies developed in this sector to digital health, pharma services, and eclinical teams. I find these teams have more opportunity than any other industry to use thoughtful marketing for differentiating from competitors, disrupting large yet slow competitors, capturing market share, and growing revenue.”

David Raunig is an accomplished leader in data science and drug development with over 28 years of experience in medical, scientific, and statistical innovation. He has been instrumental in guiding clinical trials from Phase 0 through IIb, playing a critical role in designing Statistical and Biomarker Analysis Plans for FDA and EMA submissions. Notably, David contributed to the development of five FDA-validated study biomarkers and led disease progression model development across oncology, neurodegeneration, and GI transit, among other therapeutic areas. 

With over 40 years of increasing leadership responsibility, David has held executive positions overseeing strategic planning, business development, and governance. His leadership has earned them multiple awards for team engagement and turnaround, mentoring junior and senior personnel who have achieved accelerated promotions. Additionally, David has fostered collaborations with top Key Opinion Leaders (KOLs) and prestigious institutions, such as WUSTL, Columbia University, and Johns Hopkins, while contributing to scientific and statistical advisory boards. 

Wil worked for over 35 years in clinical imaging as a Professor of Radiology, initially at the Mallinckrodt Institute in St Louis and then Temple University in Philadelphia before switching to industry and spending 5 years as a Medical Director of Icon Medical Imaging. He received an MBA from Washington University, Olin School of Business in 2000.  He has expertise and has published extensively in medical imaging, the development of magnetic resonance imaging (MRI) techniques and optimization of other imaging modalities to improve understanding of disease processes such as traumatic brain injury, stroke, and musculoskeletal disorders. As a practicing physician, Wil has been involved with clinical trials both from the clinical and the CRO sides with a specific focus on imaging endpoints. 

Ina Margaretha is based in Amsterdam and has a 25 years of experience with the fields of clinical drug development, strategic partnerships, business development, and building innovative biotech businesses and CROs in Europe.

Ina Margaretha has been developing business plans for start-ups, organizing funding (including European grants), leading R&D programs, outsourcing development and commercial strategies to develop groundbreaking therapies in the field of immunology, allergy, inflammatory diseases (including post-COVID), musculoskeletal, orphan diseases and CNS, ultimately negotiating attractive licensing deals to accelerate time to market. She has also experience in gene and cell therapies and combined medical devices.

Over the course of her career, she has created strong relationships with life science investors, built strong scientific and operational teams, and developed long term partnerships with biopharma partners to bring innovative treatments to patients.

Ina Margaretha has a Master’s Degree in Biomedical Sciences from the Leiden University Medical Centre, The Netherlands.

Andrew (Andy) brings more than 40 years’ experience in the biotech/pharmaceutical industry having initiated and built several biotech companies including Inotek Pharmaceuticals Corporation, Radikal Therapeutics, Salzman Group, Chilmark Laboratories, and Orphan Technologies, where he oversaw the entire spectrum of drug development activities, including discovery chemistry, pharmacology, and preclinical activities, manufacturing, clinical Phase I-II, as well as the US and international regulatory strategies. Andy has over 170 peer-reviewed articles, 47 patents, and was the inventor and development lead for the clinical-stage PARP-1 inhibitor. More recently Andy’s focus and interest has been on the clinical use of cannabinoids.

Rosemary has extensive sales and marketing experience in Medical Imaging, Software, Drug Development, Medical Devices, Oncology, Neuromuscular, Musculoskeletal and Metabolic diseases. With her demonstrated history in Executive Leadership, Business Development, Sales Growth, and Marketing in the medical device and pharmaceutical development industries, Rosemary excels at preparing and delivering presentations to investors as well as Board of Director members.  

François Tranquart has acquired robust experience in imaging over the past 40 years, combining extensive clinical practice and research at Tours University Hospital for 20+ years, followed by 15+ years of experience in the industry. His expertise in R&D, clinical development, and regulatory affairs in molecular imaging has been essential for the successful approval of two imaging compounds.

His academic career covers various therapeutic domains, largely dominated by oncology and cardiovascular disease. This experience encompasses the diagnostic use of contrast media and radionuclides, as well as therapy with MRgFUS, radionuclides, or drug delivery using microbubbles. This extensive activity has included 20+ Phase 2-4 clinical studies, leading to the publication of more than 170 peer-reviewed papers.

François then transitioned to industry with a leadership role in R&D and clinical development for molecular imaging and therapy using microbubbles, radiopharmaceuticals, delivery devices, software development, and contrast media manufacturing. This provided an opportunity to acquire robust experience with worldwide regulatory agencies in site inspections, clinical development pathways, clinical studies across all phases, and NDAs.

His broad medical experience is pivotal in assessing medical needs, identifying potential issues, and challenging assumptions while offering contingencies or innovative strategies for strong business development. This dual experience in academic and industry positions has provided the foundation for innovative concepts and a strategic vision leading to commercial success in molecular imaging and radioligand therapy.

Brad is a recognized expert with more than 25 years of experience in clinical trial design. His extensive experience includes a 10-year tenure at Pfizer, where he played a pivotal role in developing and implementing imaging biomarkers in clinical studies across multiple therapeutic areas. Formerly, he held the position of Vice President of Imaging and Clinical Development at ImaginAb. In this role, he was responsible for the development and clinical testing of novel PET tracers. Currently, Brad collaborates with medical device and biotech companies, providing consultancy services to implement innovative biomarkers and design robust, data-driven studies. His expertise is invaluable in guiding through critical go/no-go development decisions, ensuring they are made based on solid, actionable insights.